Phobic Disorders Clinical Trial
Official title:
A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia
We aim to (1) evaluate the effectiveness of cognitive therapy and paroxetine and their
combination, (2) investigate the patterns of change and the mechanisms of action involved
during treatment by using psycho-physiological assessments in order to delineate some of the
cognitive, behavioural and physiological mechanisms in the patients' response to CT, to
paroxetine and placebo.One hundred patients with a primary diagnosis of social phobia will be
selected and randomised into four treatment conditions. The first group (N=25) will be
treated with CT alone, the second group (N=25) with CT plus paroxetine, the third group
(N=25) with paroxetine and clinical management (TAU), the fourth group will receive placebo
and clinical management (N=25). All patients will have 12 weeks of treatment in the acute
phase, which includes 12 sessions of individual treatment for the two first groups. The 2nd
and 3rd groups will in addition have 12 weeks of drug treatment in the maintenance phase. The
4th group will have placebo for 24 weeks and clinical management. The patients will be
assessed at pre-treatment, at 12 weeks and at the end of treatment of the acute phase (12
weeks) and by the end of maintenance phase (24 weeks). Follow-up will be at 6 and 12 months.
Measures are based on all three main sources; self-report inventories, clinical assessments
by independent raters and psycho-physiological assessments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01963806 -
ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder
|
N/A | |
| Completed |
NCT00121069 -
Study of Escitalopram in the Treatment of Specific Phobia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03653923 -
Neurophysiological Correlates of Exposition Therapy in Spider Phobia
|
N/A | |
| Completed |
NCT00051220 -
Treatment for Specific Phobias in Children
|
Phase 1/Phase 2 | |
| Completed |
NCT02310152 -
Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)
|
N/A | |
| Completed |
NCT02387047 -
Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly
|
N/A | |
| Completed |
NCT00000370 -
Treatment of Social Phobia
|
N/A | |
| Completed |
NCT03012035 -
The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants
|
N/A | |
| Completed |
NCT02007694 -
Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03188575 -
Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT
|
N/A | |
| Completed |
NCT02432703 -
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
|
Phase 2 | |
| Terminated |
NCT01574014 -
Glucocorticoid Treatment for Social Phobia
|
Phase 2 | |
| Completed |
NCT00734422 -
Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT02336802 -
Threat-Avoidance Learning in Anxiety Patients
|
N/A | |
| Completed |
NCT01361074 -
In Vivo Versus Augmented Reality Exposure for Small Animal Phobia
|
N/A | |
| Completed |
NCT00104195 -
A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions
|
Phase 1 | |
| Completed |
NCT00035412 -
St. John's Wort Versus Placebo in Social Phobia
|
Phase 2 | |
| Completed |
NCT00128401 -
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
|
Phase 2 | |
| Recruiting |
NCT02020824 -
Virtual Reality and Concept of Control in the Treatment of Acrophobia
|
N/A | |
| Terminated |
NCT01623583 -
Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias
|
Phase 4 |